As the world of computing evolves, the partnership between biotechnology company Moderna and IBM takes a significant step forward in exploring groundbreaking applications of artificial intelligence and quantum computing in mRNA science. The collaboration, announced on April 20, 2023, aims to accelerate and advance mRNA research with a focus on AI and quantum computing applications.
Moderna’s CEO, Stéphane Bancel, emphasizes the company’s commitment to being at the forefront of technology, stating that their partnership with IBM will develop novel AI models to advance mRNA science and prepare for the era of quantum computing. Dr. Darío Gil, Senior Vice President and Director of IBM Research, adds that IBM’s purpose of being a catalyst for a better world aligns perfectly with this partnership.
One crucial aspect of the partnership involves applying MoLFormer, an AI foundation model designed to predict a molecule’s properties, to mRNA medicine design. By understanding the characteristics of potential mRNA medicines, MoLFormer will aid in optimizing lipid nanoparticles and mRNA. These particles encapsulate and protect mRNA as it travels within the body, instructing cells to fight diseases. Moderna and IBM will combine state-of-the-art formulation discovery with generative AI to design mRNA medicines with optimal safety and performance.
In addition to AI, the collaboration also focuses on quantum computing, an emerging technology that uses quantum mechanics principles to solve complex problems beyond the capabilities of classical computers. Moderna scientists will explore quantum technology’s potential applications in addressing scientific challenges, participating in IBM’s Quantum Accelerator program and IBM Quantum Network. IBM will provide access to quantum computing systems and expertise to help Moderna explore life sciences use-cases powered by quantum technologies.
Over the past decade, Moderna has grown from a research-stage company to an enterprise with a diverse clinical portfolio of vaccines and therapeutics. Their mRNA platform has enabled the development of treatments for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. With the authorized use and approval of one of the earliest and most effective COVID-19 vaccines, Moderna’s capabilities have had a significant global impact.
IBM, a global leader in hybrid cloud, AI, and consulting expertise, serves clients in over 175 countries. Their breakthrough innovations in AI, quantum computing, industry-specific cloud solutions, and consulting deliver open and flexible options to clients.
This partnership marks a promising step in harnessing the power of AI and quantum computing to revolutionize mRNA science, paving the way for potential breakthroughs in mRNA medicines.
Read more business news from our press team to stay up to date with the disruptions of AI.
